stockrow
Monday 9 November 2026
Export NGEN’s income statement to Excel — free account
NervGen Pharma Corp.
NGEN- EPS
- +192.2%
- Free cash flow
- −48.1%
Quarter to June 2026, against a year earlier
1.33
0.01
+0.76%
Follow NGEN
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
1.12 | 1.32 |
Net Debt/EBITDA |
0.70 | 0.95 |
Debt/Assets |
0.04% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.70 | 0.44 |
Capex/Depreciation |
0.00 | 0.00 |
| 0.00% | (1,037.45%) | |
| 0.00% | (205.27%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(1,136.82%) | (805.79%) |
Average Days of Receivables |
0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.02 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(0.18) | (0.19) |
Cash per Share |
0.19 | 0.22 |
Shareholders Equity per Share |
0.03 | 0.06 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.03 | 0.06 |
Free Cash Flow |
(12.29) | (13.96) |
Working Capital |
1.54 | 3.93 |
Net Current Asset Value |
1.54 | 3.93 |
| Other line items | ||
Quick Ratio |
1.05 | 1.28 |
Depreciation/Fixed assets |
0.00 | 0.00 |
Cash ROIC |
(84.42%) | (69.70%) |
Accounts Receivable Turnover |
— | 0.00 |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.18) | (0.19) |
Capex per Share |
0.00 | 0.00 |
Average Receivables |
— | 0.18 |
Average Payables |
— | 3.47 |
Average Assets |
— | 15.42 |
Average Common Equity |
— | 3.05 |
Columns are period end dates · fundamentals updated 2 Nov 2026